The ROAR trial tested the hypothesis that returning familial hypercholesterolemia-associated genetic results leads to ...
— Novel, third-generation PCSK9 inhibitor designed to help patients more easily achieve lifelong cholesterol goals with robust and sustained LDL-C reductions of 50% or more — — Approved for adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback